צינקול טבליות בציפוי אנטרי
sam-on ltd - zinc as sulfate - טבליה - zinc as sulfate 50 mg - zinc sulfate - zinc sulfate - zinc supplement.
אי-זי-פק
promedico ltd - barium sulfate - אבקה להכנת תרחיף - barium sulfate 96 %w/w - barium sulfate with suspending agents - barium sulfate with suspending agents - single - contrast radiography of the oesophagus stomach duodenum and small bowel. for use only in x-ray departments.
אי.זי.הדי
promedico ltd - barium sulfate - אבקה להכנת תרחיף - barium sulfate 98.3845 %w/w - barium sulfate without suspending agents - barium sulfate without suspending agents - for double contrast radiography of the oesophagus, stomach and duodenum.
פוליבר acb
promedico ltd - barium sulfate - אבקה להכנת תרחיף - barium sulfate 96.476 %w/w - barium sulfate without suspending agents - barium sulfate without suspending agents - for rectal administration (enema) as a radio-opaque agent for x-ray visualisation of the lower gastro-intestinal tract. it is designed for both single contrast barium enema and air-double contrast enema usage.
אי-זי-קאט
promedico ltd - barium sulfate - תרחיף - barium sulfate 4.9224 %w/v - barium sulfate containing x-ray contrast media - for use in x-ray departments.opacification of the gastro intestinal tract prior to computerized axial tomography.
ניטיודוט
hope pharmaceuticals ltd, israel - sodium nitrite; sodium thiosulfate - תמיסה להזרקה - sodium thiosulfate 250 mg / 1 ml; sodium nitrite 30 mg / 1 ml - thiosulfate
סודיום תיוסולפט 250 מגמל
hope pharmaceuticals ltd, israel - sodium thiosulfate - תמיסה להזרקה - sodium thiosulfate 250 mg / 1 ml - thiosulfate
קוסליוגו 10 מג
astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 10 mg - selumetinib
קוסליוגו 25 מג
astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 25 mg - selumetinib
קלופידוגרל טבע
teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or